← Back to patent-cliff list
Givosiran
Tier C — Watch / tradeGivosiran
Alnylam Pharmaceuticals Inc
Originator
2019
First approval
-
Expiry (public)
$0.31B ▲
Peak sales
Nucleic acid drug
Type
Targets：ALAS1
Brand：Givlaari
Indications (approved)：Hepatic porphyria, Acute intermittent porphyria
Regional status
US
Approved
2019-11-20
EU
Approved
2020-03-02
China
-
Japan
Approved
2021-06-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Givosiran?
Approved indications include: Hepatic porphyria, Acute intermittent porphyria.
When does the Givosiran patent expire?
No public expiry year is available for Givosiran yet; this page updates once verified.
How do I get a quote for Givosiran intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29